ATE484510T1 - Kondensierte imidazolderivate als aromataseinhibitoren - Google Patents

Kondensierte imidazolderivate als aromataseinhibitoren

Info

Publication number
ATE484510T1
ATE484510T1 AT07728053T AT07728053T ATE484510T1 AT E484510 T1 ATE484510 T1 AT E484510T1 AT 07728053 T AT07728053 T AT 07728053T AT 07728053 T AT07728053 T AT 07728053T AT E484510 T1 ATE484510 T1 AT E484510T1
Authority
AT
Austria
Prior art keywords
aromates
inhibitors
imidazole derivatives
condensed imidazole
condensed
Prior art date
Application number
AT07728053T
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Aleksandar Stojanovic
Christiane Marti
Stefan Stutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE484510T1 publication Critical patent/ATE484510T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT07728053T 2006-04-12 2007-04-12 Kondensierte imidazolderivate als aromataseinhibitoren ATE484510T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH6172006 2006-04-12
PCT/EP2007/053586 WO2007116100A1 (en) 2006-04-12 2007-04-12 Condensed imidazole derivatives as aromatase inhibitors

Publications (1)

Publication Number Publication Date
ATE484510T1 true ATE484510T1 (de) 2010-10-15

Family

ID=38171569

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07728053T ATE484510T1 (de) 2006-04-12 2007-04-12 Kondensierte imidazolderivate als aromataseinhibitoren
AT07728050T ATE479692T1 (de) 2006-04-12 2007-04-12 Kondensierte imidazolderivate als aldosteronsynthaseinhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07728050T ATE479692T1 (de) 2006-04-12 2007-04-12 Kondensierte imidazolderivate als aldosteronsynthaseinhibitoren

Country Status (14)

Country Link
US (3) US7799780B2 (de)
EP (2) EP2004658B1 (de)
JP (2) JP2010523465A (de)
CN (2) CN101421278A (de)
AR (1) AR060591A1 (de)
AT (2) ATE484510T1 (de)
BR (2) BRPI0710596A2 (de)
CA (2) CA2649214A1 (de)
DE (2) DE602007008860D1 (de)
ES (1) ES2352092T3 (de)
IL (2) IL193065A0 (de)
PL (1) PL2004657T3 (de)
TW (1) TW200808812A (de)
WO (2) WO2007116097A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511621A (pt) * 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
CN101180344B (zh) 2005-03-24 2012-01-11 株式会社普利司通 具有低挥发性有机化合物（voc）释放的配混二氧化硅补强橡胶
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
CA2652346A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
US8962746B2 (en) 2007-12-27 2015-02-24 Bridgestone Corporation Methods of making blocked-mercapto alkoxy-modified silsesquioxane compounds
US8794282B2 (en) 2007-12-31 2014-08-05 Bridgestone Corporation Amino alkoxy-modified silsesquioxane adhesives for improved metal adhesion and metal adhesion retention to cured rubber
EP2435402B1 (de) 2009-05-28 2016-04-13 Novartis AG Substituierte aminobuttersäurederivate als neprilysininhibitoren
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
CN104093709B (zh) * 2012-02-13 2017-09-22 霍夫曼-拉罗奇有限公司 作为醛固酮合酶抑制剂的咪唑基酮衍生物
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
LT2956464T (lt) 2013-02-14 2018-07-10 Novartis Ag Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
WO2016109625A1 (en) 2014-12-31 2016-07-07 Bridgestone Corporation Amino alkoxy-modified silsesquioxane adhesives for adhering steel alloy to rubber
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
CN113166204A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS579787A (en) 1980-06-20 1982-01-19 Ss Pharmaceut Co Ltd Thiazinobenzimidazole derivative and its preparation
JPH0670064B2 (ja) 1986-12-08 1994-09-07 三井石油化学工業株式会社 二環性イミダゾ−ル誘導体
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
EP1282410A2 (de) * 2000-04-12 2003-02-12 Novartis AG Neue medizinische verwendung von aldosteron-synthase-inhibitoren, alleine oder in kombination mit at1-rezeptor-antagonisten
ES2270143T3 (es) * 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
BRPI0511621A (pt) 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
ATE490241T1 (de) * 2004-05-28 2010-12-15 Novartis Ag Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren
CA2568165A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds

Also Published As

Publication number Publication date
CN101421278A (zh) 2009-04-29
US20100305110A1 (en) 2010-12-02
EP2004658B1 (de) 2010-10-13
AR060591A1 (es) 2008-07-02
US7795253B2 (en) 2010-09-14
WO2007116100A1 (en) 2007-10-18
CN101415716B (zh) 2012-12-12
BRPI0709948A2 (pt) 2011-08-02
IL193065A0 (en) 2009-02-11
CN101415716A (zh) 2009-04-22
ES2352092T3 (es) 2011-02-15
EP2004658A1 (de) 2008-12-24
JP2010523465A (ja) 2010-07-15
JP4980417B2 (ja) 2012-07-18
JP2009532442A (ja) 2009-09-10
CA2649214A1 (en) 2007-10-18
TW200808812A (en) 2008-02-16
US8076327B2 (en) 2011-12-13
US7799780B2 (en) 2010-09-21
EP2004657B1 (de) 2010-09-01
BRPI0710596A2 (pt) 2011-08-16
PL2004657T3 (pl) 2011-02-28
US20090012068A1 (en) 2009-01-08
EP2004657A1 (de) 2008-12-24
CA2641473A1 (en) 2007-10-18
CA2641473C (en) 2011-11-01
DE602007008860D1 (de) 2010-10-14
DE602007009812D1 (de) 2010-11-25
ATE479692T1 (de) 2010-09-15
US20090048241A1 (en) 2009-02-19
IL194582A0 (en) 2009-08-03
WO2007116097A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
ATE484510T1 (de) Kondensierte imidazolderivate als aromataseinhibitoren
CY2017016I2 (el) Αναστολεις πρωτεασωματος
ATE523505T1 (de) Imidazol-derivate als tafia-inhibitoren
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
DE602006011363D1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
ATE493411T1 (de) Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
ATE510825T1 (de) Acylaminopyrazole als fgfr-inhibitoren
ATE537147T1 (de) Azabiphenylaminobenzoesäurederivate als dhodh- inhibitoren
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
BRPI0817609A2 (pt) Derivados de imidazol
ATE517101T1 (de) Als mmp-inhibitoren verwendete hydantoinderivate
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
ATE526324T1 (de) Substituierte imidazolverbindungen als ksp- inhibitoren
CR10879A (es) Cyclized derivatives as eg-5 inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties